心衰与心肌病中循证医学与个体化医疗的调和观点
本文为综述,围绕心力衰竭和遗传性心肌病,分析循证医学与个体化医学的范式冲突与互补关系。心衰领域循证证据较充分,而遗传性心肌病高质量证据相对稀缺,更依赖个体化策略。文章提出动态、情境敏感的概念框架,以整合标准化诊疗与个体化管理。
要点
- 心衰领域循证医学证据广泛且稳健,适合以指南为导向的标准化治疗。
- 遗传性心肌病高质量循证证据相对稀缺,常进展为心衰,需要强调个体化医学价值。
- 临床可尝试动态、情境敏感的方式整合群体证据与患者个体特征,优化预后。
核心结论
- 循证医学与个体化医学并非对立,而是可以在心衰和心肌病管理中形成互补。
- 可为标准化诊疗与个体化管理建立动态、情境敏感的概念框架,兼顾群体证据与患者独特性。
研究设计与样本
- 本文为综述,批判性分析循证医学与个体化医学在心力衰竭和心肌病中的哲学基础与临床意义。
- 文中探讨了旨在弥合标准化诊疗与个体化管理之间差距的新兴策略。
主要发现
- 心衰领域循证医学广泛且稳健,遗传性心肌病高质量证据相对稀缺且常导致心衰。
- 遗传性心肌病证据不足进一步凸显了个体化医学在该领域的关键作用。
- 循证医学强调群体平均水平,个体化医学关注患者超越群体平均值的独特性。
关键数值与推荐
- 心衰管理以稳健临床试验和指南导向药物治疗为循证实践基础。
- 遗传性心肌病常进展为心衰,但缺少与心衰相当的稳健高质量证据。
临床怎么用
- 临床决策可同时参考指南导向治疗与患者具体病理生理和个体轨迹。
- 在证据稀缺的遗传性心肌病情境中,优先结合个体化评估而非机械套用群体规则。
局限性
- 心衰与遗传性心肌病病理生理复杂且个体轨迹差异大,单一范式难以完全覆盖。
- 遗传性心肌病领域因高质量证据相对稀缺,标准化诊疗的外部效度存在局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the modern era of cardiovascular medicine, clinicians and researchers stand at a pivotal crossroads between the paradigms of evidence-based medicine (EBM) and personalized medicine (PM). This tension is particularly palpable in the management of heart failure (HF) and inherited cardiomyopathies, heterogeneous conditions with complex pathophysiology and variable individual trajectories. While EBM has shaped practice through robust clinical trials and guideline-directed therapies, PM challenges us to consider the uniqueness of the patient beyond population averages. This dilemma is clear when considering that EBM is extensive and robust in the field of HF, instead, high-quality evidence remains relatively scarce for inherited cardiomyopathies, which may often result in HF, further highlighting the critical role of PM in this domain. The divergence underscores a critical epistemological and practical issue: how can clinicians reconcile the generalizability of EBM with the specificity demanded by PM? This review critically examines the philosophical foundations and clinical implications of this paradigm interplay, with a focus on HF and cardiomyopathies. It explores emerging strategies that aim to bridge the gap between standardized care and individualized management. Finally, it proposes a conceptual framework for harmonizing EBM and PM, advocating for a dynamic, context-sensitive approach that leverages the strengths of both paradigms to optimize patient outcomes in an era of personalized cardiovascular care.
引用
- Finocchiaro, Perotto, Merlo, et al. Reconciling evidence-based and personalized medicine: perspectives in heart failure and cardiomyopathies. Eur Heart J. 2026. PMID: 42702502. doi:10.1093/eurheartj/ehag596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。